ClinicalTrials.gg
CompletedNCT02272777Updated Aug 19, 2019Results posted

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

A Phase 3 interventional study of Imatinib and Nilotinib in Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-19.

Primary conditionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Why
  1. The study's title name Leukemia, Myelogenous, Chronic, BCR-ABL Positive, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2014, registered Oct 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
9th of 66
225 · median 55
Started
2014
with 4 others
Phase 3
15 of 66
none open now
Registered
53rd of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 9th largest by enrollment, is one of 5 that started in 2014, is one of 15 in phase 3, and was the 53rd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The extension study followed the core study CAMN107ECN02 (NCT01275196). which is an open-label, two armed study. All patients enrolled in this extension study were able to benefit from the treatment given in CAMN107ECN02 per investigator's evaluation. Therefore, in this extension study patient continued treatment of the drug (imatinib or nilotinib) which they were taking at the end of CAMN107ECN02. Treatment arms in CAMN107ECN02 were retained. As long as EC approval and agreement from investigators were obtained, the selected sites for CAMN107ECN02 were applied in this extension study.

Read the detailed description

Up to 230 patients who benefited from the core study treatment (imatinib or nilotinib), at Investigator's discretion, were enrolled into this extension study. The patients continued receiving the open-label drugs that they were taken by the end of core study. Treatment arms in the core study were retained. No crossover between the arms was allowed.

The extension study started from the first patient last dose date in the core study and ends at the time of nilotinib was commercially available in China as a first line treatment. Eligibility evaluations were given for each patient before the enrollment. Follow-up visits at a frequency of 6 months were required to report AE, SAE and pregnancy only. No efficacy data were collected in the extension study since full efficacy had already been analyzed in the core study.

03

Conditions studied

  • Leukemia

Keywords

  • Nilotinib
  • AMN107
  • Tasigna
  • Imatinib
  • STI571
  • Gleevec/Glivec
  • BCR-ABL Positive
  • Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
  • Chronic myelogenous leukemia
  • Chronic myeloid leukemia
  • Chronic myelocytic leukemia
  • Acute Lymphoblastic Leukemia (ALL) Philadelphia chromosome positive
  • Acute Lymphoid Leukemia
  • suboptimal molecular response
04

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Reclassified

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's enrollment of 225 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Patient is currently on treatment in the core study CAMN107ECN02
  2. Patient who continues to derive benefit more than risk from the study treatment he/she takes in CAMN107ECN02, in the opinion of the investigator at the end of the study
  3. Written must be obtained prior to enrolling in the extension study

Key Exclusion Criteria:

  1. Progression to CML-AP or BC
  2. Patient whose treatment assigned in CAMN107ECN02 is not appropriate any longer, per investigator's assessment.
  3. History of non-compliance to medical regimens, or patients who are considered potentially unreliable and/or not cooperative.
  4. Women who are (a) pregnant and(b) women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and at least 14 days after last dose of study medication. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.
    • Combination of any two of the following (a+b or a+c, or b+c):

      1. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.
      2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
      3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Active comparator
    Imatinib

    Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.

    Drug: Imatinib

  • Experimental
    Nilotinib

    Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.

    Drug: Nilotinib

Interventions

  • Imatinib 400mg QD,300mg QD or 600mg QD

    Also known as: STI571, Gleevec/Glivec

  • Nilotinib 300mg BID or 400mg QD

    Also known as: AMN107, Tasigna

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Clinically significant changes in laboratory values and vital signs were reported as AEs or SAEs, as appropriate. Only descriptive analysis.

    Time frame: From first dose of study treatment to 30 days after last dose of study treatment, up to 31 months

08

Results

Posted Aug 19, 2019

Participant flow

This study was conducted at 13 centers in China.

Participant flow — Overall Study
MilestoneImatinibNilotinib
Started112113
Completed108109
Not completed44
Withdrew: Adverse event01
Withdrew: Withdrawal by subject03
Withdrew: Lost to follow-up20
Withdrew: Other20

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Clinically significant changes in laboratory values and vital signs were reported as AEs or SAEs, as appropriate. Only descriptive analysis.

Time frame:
From first dose of study treatment to 30 days after last dose of study treatment, up to 31 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsImatinibNilotinib
Adverse Events (AEs)8284
Serious Adverse Events (SAEs)13
Fatal SAEs00
AEs leading to drug discontinuation01
AEs leading to dose adjustment/interruption1717

Adverse events

Collected over Adverse Events were collected for the maximum duration of participants' treatment exposure up to 29.3 months, plus 30 days follow up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib0/112 (0%)1/112 (0.9%)74/112 (66.1%)
Nilotinib0/113 (0%)3/113 (2.7%)68/113 (60.2%)
Most frequent serious events
Most frequent serious events
EventImatinibNilotinib
CholelithiasisHepatobiliary disorders1/1120/113
EnteritisGastrointestinal disorders0/1121/113
FractureMusculoskeletal and connective tissue disorders0/1121/113
Cerebral infarctionNervous system disorders0/1121/113
Most frequent other events
Showing 10 of 31
Most frequent other events
EventImatinibNilotinib
Blood bilirubin increasedInvestigations2/11224/113
Blood triglycerides increasedInvestigations12/11217/113
AstheniaGeneral disorders15/11210/113
Blood cholesterol increasedInvestigations3/11211/113
LeukopeniaBlood and lymphatic system disorders10/1122/113
Blood phosphorus decreasedInvestigations10/1124/113
White blood cell count decreasedInvestigations10/1120/113
Memory impairmentNervous system disorders10/11210/113
AnaemiaBlood and lymphatic system disorders9/1124/113
Upper respiratory tract infectionInfections and infestations9/1127/113

Baseline characteristics

The Safety Set was the only analysis set for this study.

Age, Continuous
Age, Continuous(Years)ImatinibNilotinibTotal
Mean43.3 ± 12.845.5 ± 12.744.4 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)ImatinibNilotinibTotal
Female453883
Male6775142
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ImatinibNilotinibTotal
Chinese112113225
09

Study locations

12 sites
  • Novartis Investigative Site
    Guangzhou, Guangdong 51000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310003, China
  • Novartis Investigative Site
    Beijing, 100044, China
  • Novartis Investigative Site
    Fuzhou, 350001, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200433, China
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jan 2017, 30 months.

Results were first posted in Aug 2019, 2 years 6 months after primary completion.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2014
First posted
Oct 23, 2014
StartActual
Jul 17, 2014
Primary completionActual
Jan 30, 2017
CompletionActual
Jan 30, 2017
Results first posted
Aug 19, 2019
Last update
Aug 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02272777
Responsible party
Sponsor
First posted
Oct 23, 2014
Start date
Jul 17, 2014
Primary completion
Jan 30, 2017
Completion
Jan 30, 2017
Results posted
Aug 19, 2019
Last update
Aug 19, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion